Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tesaro Inc (TSRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,563,026
  • Shares Outstanding, K 54,380
  • Annual Sales, $ 44,820 K
  • Annual Income, $ -387,470 K
  • 36-Month Beta 1.64
  • Price/Sales 103.25
  • Price/Cash Flow 0.00
  • Price/Book 11.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.35 +0.67%
on 11/20/17
119.00 -29.49%
on 10/30/17
-32.49 (-27.91%)
since 10/20/17
3-Month
83.35 +0.67%
on 11/20/17
136.45 -38.50%
on 09/06/17
-36.71 (-30.43%)
since 08/22/17
52-Week
83.35 +0.67%
on 11/20/17
192.94 -56.51%
on 02/21/17
-47.36 (-36.08%)
since 11/22/16

Most Recent Stories

More News
TESARO Announces Participation in Two Investor Conferences

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:

TSRO : 83.91 (-1.40%)
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

CELG : 105.16 (+0.63%)
CYTK : 7.97 (-3.33%)
RARE : 48.94 (+1.68%)
ACOR : 20.25 (+0.75%)
TSRO : 83.91 (-1.40%)
UTHR : 125.41 (unch)
BIIB : 309.80 (+0.24%)
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU

TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.

AZN : 33.83 (+0.30%)
MRK : 54.37 (+0.18%)
CLVS : 61.52 (+0.57%)
TSRO : 83.91 (-1.40%)
TESARO Secures $500 Million Non-Dilutive Term Loan Financing

TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has entered into a definitive term loan agreement with BIOPHARMA CREDIT PLC and BIOPHARMA CREDIT INVESTMENTS...

TSRO : 83.91 (-1.40%)
TESARO, Inc. Co-Founders named Entrepreneur Of The Year® 2017 National Overall Award winners

Lonnie Moulder, CEO and Co-founder, and Mary Lynne Hedley, PhD, President, COO and Co-founder, of TESARO, Inc. have been named Entrepreneur Of The Year® 2017 National Overall Award winners. Now in its...

TSRO : 83.91 (-1.40%)
TESARO's Mary Lynne Hedley and Lonnie Moulder Named EY National Entrepreneurs of the Year(R)

TESARO, Inc., an oncology-focused biopharmaceutical company, is proud to announce that co-founders Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, have been named EY Entrepreneurs...

TSRO : 83.91 (-1.40%)
TESARO Announces European Commission Approval of ZEJULA(R) for Women With Recurrent Ovarian Cancer

-- ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status

TSRO : 83.91 (-1.40%)
TESARO Announces Third-Quarter 2017 Operating Results

-- ZEJULA was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 million

TSRO : 83.91 (-1.40%)
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss

Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.

AZN : 33.83 (+0.30%)
CLVS : 61.52 (+0.57%)
TSRO : 83.91 (-1.40%)
BMY : 61.14 (-0.16%)
OPKO Health Licensee TESARO Announces FDA Approval of VARUBI(R) IV for Delayed Nausea and Vomiting Associated with Chemotherapy

OPKO Health, Inc. (NASDAQ:OPK) announces that its licensee, TESARO, Inc. (Nasdaq:TSRO), received U.S. Food and Drug Administration (FDA) approval for VARUBI(R) (rolapitant) IV in combination with other...

OPK : 4.80 (+0.42%)
TSRO : 83.91 (-1.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor...

See More

Key Turning Points

2nd Resistance Point 87.06
1st Resistance Point 85.48
Last Price 83.91
1st Support Level 82.87
2nd Support Level 81.84

See More

52-Week High 192.94
Fibonacci 61.8% 151.08
Fibonacci 50% 138.15
Fibonacci 38.2% 125.21
Last Price 83.91
52-Week Low 83.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart